# A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)

> **NCT02574078** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 341 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Bevacizumab
- **DRUG:** Pemetrexed
- **OTHER:** Best Supportive Care
- **DRUG:** nab-Paclitaxel
- **DRUG:** Paclitaxel
- **DRUG:** Docetaxel
- **DRUG:** Gemcitabine
- **DRUG:** Erlotinib
- **DRUG:** Crizotinib
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT02574078
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-23
- **Primary completion:** 2020-04-15
- **Final completion:** 2020-04-15
- **Target enrollment:** 341 (ACTUAL)
- **Last updated:** 2021-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02574078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02574078, "A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02574078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*